AstraZeneca's baxdrostat meets main goal in high blood pressure study – Reuters

Written by

admin

in

  1. AstraZeneca’s baxdrostat meets main goal in high blood pressure study  Reuters
  2. New Pill Lowers Stubborn Blood Pressure and May Slow Kidney Disease  SciTechDaily
  3. AstraZeneca : Baxdrostat met primary endpoint in Bax24 Ph3 trial  MarketScreener
  4. AstraZeneca’s Baxdrostat Study: A Potential Game-Changer for Resistant Hypertension  TipRanks

Continue Reading

More posts